Literature DB >> 2580329

Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.

G Bagdy, A Perényi, E Frecska, K Révai, Z Papp, M I Fekete, M Arató.   

Abstract

Dopamine (DA), homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC), noradrenaline (NA), and 5-hydroxyindolacetic acid (5HIAA) were measured in cerebrospinal fluid (CSF) of 15 chronic schizophrenic patients before and 2 weeks after withdrawal of long-term neuroleptic treatment. Total neuroleptic-like activity in serum (NLA) was determined at the same times. Levels of DA and its metabolites (DOPAC and HVA) and NA were significantly reduced after the discontinuation of neuroleptic treatment. No change was observed in 5HIAA values. NLA was substantially reduced, but still remained detectable. The decrease in DA, DOPAC, and HVA all showed positive correlations with each other, and correlated negatively with NLA measured after 2 weeks. Our data implies that the decrease in DA turnover is the result of the discontinuance of DA receptor blockade, while the change in NA level is independent of it.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580329     DOI: 10.1007/bf00427323

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Determination of nanogram amounts of homovanillic acid in the central nervous system with a rapid semiautomated fluorometric method.

Authors:  B H Westerink; J Korf
Journal:  Biochem Med       Date:  1975-02

2.  Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.

Authors:  R M Post; F K Goodwin
Journal:  Science       Date:  1975-10-31       Impact factor: 47.728

3.  Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene.

Authors:  L Bjerkenstedt; B Gullberg; C Härnryd; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1977-10-11

4.  Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate.

Authors:  M C Nowycky; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

5.  The effect of pimozide on CSF norepinephrine in schizophrenia.

Authors:  D E Sternberg; D P van Kammen; C R Lake; J C Ballenger; S R Marder; W E Bunney
Journal:  Am J Psychiatry       Date:  1981-08       Impact factor: 18.112

6.  Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine.

Authors:  G Gianutsos; J E Thornburg; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1976-11-24       Impact factor: 4.530

7.  Comparative analysis of indices of central dopaminergic functions in man.

Authors:  G Bagdy; M Arató; K Baraczka; M I Fekete
Journal:  Life Sci       Date:  1983-06-06       Impact factor: 5.037

8.  Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.

Authors:  G Sedvall
Journal:  Prog Biochem Pharmacol       Date:  1980

9.  Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey).

Authors:  N G Bacopoulos; D E Redmond; J Baulu; R H Roth
Journal:  J Pharmacol Exp Ther       Date:  1980-01       Impact factor: 4.030

10.  A column chromatographic method for the determination of 5-hydroxytryptamine (serotonin) and 5-hydroxyindole acetic acid in cerebrospinal fluid.

Authors:  V F Kemerer; K M Lichtenfeld; T R Koch
Journal:  Clin Chim Acta       Date:  1979-02-15       Impact factor: 3.786

View more
  3 in total

1.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizophrenia and Parkinson's disease.

Authors:  Giulio Scigliano; Gabriele Ronchetti; Floriano Girotti
Journal:  Neurol Sci       Date:  2008-04-01       Impact factor: 3.307

3.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.